

AD _____

Award Number: DAMD17-01-1-0199

TITLE: Use of a Transgenic Mouse Model with a Regulatable
Estrogen Receptor Alpha (ER) to Study the Role of ER in Mammary
Gland Development and Cancer

PRINCIPAL INVESTIGATOR: Sonia L. Sugg, M.D.

CONTRACTING ORGANIZATION: Medical College of Wisconsin
Milwaukee, WI 53226-0509

REPORT DATE: September 2004

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE September 2004	3. REPORT TYPE AND DATES COVERED Final(20 Aug 2001 - 19 Aug 2004)	
4. TITLE AND SUBTITLE Use of a Transgenic Mouse Model with a Regulatable Estrogen Receptor Alpha (ER) to Study the Role of ER in Mammary Gland Development and Cancer			5. FUNDING NUMBERS DAMD17-01-1-0199	
6. AUTHOR(S) Sonia L. Sugg, M.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Medical College of Wisconsin Milwaukee, WI 53226-0509 E-Mail: ssugg@mcw.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES Original contains color plates: ALL DTIC reproductions will be in black and white				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) Estrogen (E2) is required for the development of breast cancer, but there are few animal models to study its mechanism of action in vivo. We hypothesize that the timing of estrogen receptor α (ER α) action is crucial in normal mammary gland development and tumorigenesis. Therefore, a transgenic mouse model with a regulatable ER α is being generated. In vitro, a mutant ER α (525L) has a severely attenuated response to endogenous estradiol (E2) but a wild-type (WT) response to diethylstilbestrol (DES). Gene targeting was used to insert 525L into the WT ER gene. Positive clones were injected into mouse blastocysts and chimeras were generated. There has been no germline transmission so far. Additional injections and further breeding continues. The resultant transgenic mouse will enable us to study how the timing of ER activation modulates normal mammary maturation and the development of mammary cancers.				
14. SUBJECT TERMS Breast cancer, estrogen receptor				15. NUMBER OF PAGES 11
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

TABLE OF CONTENTS

Cover.....	1
SF 298.....	2
Introduction.....	4
Body.....	4-9
Key Research Accomplishments.....	10
Reportable Outcomes.....	10
Conclusions.....	10
References.....	11

INTRODUCTION


Estrogen and its receptor are required for normal breast development and are important in the treatment and prevention of breast cancer. However, there are few suitable animal models to study the role of ER activation in the breast development and cancer. We developed a mutant ER having a severely attenuated response to endogenous estradiol while demonstrating a wild-type response to a synthetic estrogen agonist *in vitro*. This was due to a difference in binding affinity. We postulate that the timing and nature of estrogen action is crucial in normal mammary gland development and tumorigenesis. We are proposing a transgenic mouse model with a regulatable ER to test this hypothesis. Our specific aims are to 1) Develop transgenic mice using gene-targeting techniques expressing only the ligand discriminating mutant ER. 2) Define the contribution of ligand induced transcriptional activation of ER in the development of normal mammary gland. 3) Investigate how the timing of ER activation modulates the development of genetically and chemically induced mammary cancers. The mutant ER mice are uniquely suited to study the role of ligand independent ER activation *in vivo*, and will also be useful in studying reproductive tract development and behavior.

BODY

Task 1. Transgenic mice expressing only a mutant ER with ligand discrimination will be developed. (months 1 - 12)

- a) Mouse ER genomic DNA will be cloned. A targeting construct (8 to 10 kb) will be generated.

Construct A (MCW): The 15 kb construct is composed of mouse genomic sequence from ER α (exons 8-9 and external downstream sequence), cloned into the pZero vector (Invitrogen) at the multiple cloning site, XhoI (5' end of insert) and HindIII (3' end of insert). A Neomycin resistance cassette, consisting of the PGK promoter, neo open reading frame and poly A tail sequence, is found approximately 1.2 kb downstream of exon 9 in reverse orientation at a BamHI site found in the genomic DNA. For removal with Cre-recombinase, the Neo cassette was flanked by LoxP sites (Figure 1). This construct was provided by our collaborators Deborah Swope and Ken Korach¹. Approximate restriction enzyme sites and distances between sites were determined by sequencing and restriction enzyme/DNA gel analysis.



Construct B (Chicago): An 11.5 kilobase ER α construct containing the G525L mutation (purple bar in green exon 9 box), an 18 bp 6xHis-tag epitope, and an extra XbaI site, was engineered to facilitate homologous recombination into the mouse genome (Figure 2). The original construct was obtained from Dr. Kenneth Korach¹ and the G525L mutation was inserted in our laboratory by site directed mutagenesis. We also inserted an ACN cassette into the targeting construct, obtained from Dr.

Wondisford at the University of Chicago, which contained a testis-specific promoter (tACE), Cre structural gene, mouse RNA polymerase gene, and neo cassette, flanked at the 5' and 3' ends by loxP sites² (Figure 2).




Fig. 2

Mutagenesis: Mutagenesis was performed by PCR using Qiagen's site directed mutagenesis kit. Three rounds of mutagenesis were performed following the kit's instructions. Briefly, primers were designed using MacVector to 1) alter the coding sequence at codon 525 to convert glycine (G) to leucine (L). 2) Create a novel XbaI site in exon 9 while maintaining the amino acid sequence. 3) Remove a nucleotide insertion event (4G→3G) near the end of exon 9 that was discovered upon sequencing. Each round of mutagenesis was performed as directed, with the PCR extension time expanded to accommodate 15 kb.

Ligand binding characterization of G525L mutation: We hypothesized that the ligand discrimination of G525L is a result of differences in binding affinity between E2 and DES present in G525L and not in WT ER α . Charcoal assays were used to determine saturation binding characteristics. The G525L mutant receptor had a K_d of 0.03nM with DES, compared with a K_d of 12.5nM with E2. In contrast, the WT receptor had a K_d of 0.04 with DES, and a K_d of 0.12nM with E2.

Characterization of dominant negative effects of G525L mutation: We were concerned that our inability to obtain germline transmission using 2 different constructs could be due to a possible dominant negative effect of the G525L mutation on wild type ER, thus preventing normal fetal development, even in the heterozygous state. To examine if mutant G525L ER α will exert a dominant negative effect on the wild type receptor in the heterozygous






Fig. 3

mice, a standard luciferase dominant negative experiment with various ratios of wild type to mutant G525L ER α was performed (Fig 3). Results indicate a dominant negative effect is unlikely.

Treatment of a potential dominant negative effect. Luciferase assays with ER-negative Ishikawa cells, cotransfected with mutant G525L ER α and an ERE-reporter, showed transcription was not stimulated by low concentrations of 17 β -estradiol (E2), but was stimulated by diethylstilbestrol (DES) or genistein (Fig 4). This demonstrates DES or genistein could be administered to heterozygous mutant G525L ER α mice to prevent a possible dominant negative effect.



Characterization of ligand-independent pathways of G525L ER α . We expect the classical ligand-dependent ER α signaling pathways to not be stimulated in G525L ER α mutant mice since the endogenous estrogens will not be able to bind to ER α . However, since the AF1 region could still be phosphorylated, we expect some of the ligand-independent and nongenomic pathways could still be active. Therefore assays were performed to examine the effects of the ligand independent and nongenomic pathways with mutant ER α . Luciferase assays with ER-negative Ishikawa cells, cotransfected with wild type or mutant G525L ER α and an ERE-reporter and treated with various concentrations of epidermal growth factor (EGF) in 2.5% serum, showed similar transcriptional responses (Fig 5). This preliminary study indicates the mutant G525L ER α ligand-independent pathways are functional.



b) Mice transgenic and homozygous for mutant ER will be generated.

A two-pronged effort, with 2 different targeting constructs, was started at MCW and the University of Chicago. The rationale was to increase the probability of, and decrease the time required to successfully generating a transgenic mouse.

1) Work performed using targeting construct A.

Table 1

A 15 kb G525L mutant ER targeting construct was used to generate 18/380 (4.7%) positive ES cell clones, as detected by 5' probe Southern blot screening. The positive clones were further confirmed by 3' external probe Southern hybridization¹, PCR of exon 9 followed by restriction enzyme XbaI digest, G525L mutation sequencing, and PCR of the neo selection marker (see

ES Clone#	Southern/5'probe	Seq.PCR/XbaI	Southern/3'probe	Mutation Sequencing	Southern/Neo
#362	+++++		+++	+	+
#29	++++		+++	+	+
#2	++++		-	N/A	+
#200	++++		+++	+	+
#110	+++		++	+	+
#130	+++		-	+	+
#134	+++	non cut	N/A	N/A	+
#175	+++		-	N/A	+
#241	+++		+	+	+
#244	+++		+++	+	+
#269	+++		-	N/A	+
#299	+++		+++	+	+
#28	++	non cut	N/A	N/A	+
#34	++		-	N/A	+
#225	++	non cut	N/A	N/A	+
#257	++		++	+	+
#331	++	non cut	N/A	N/A	+
#338	++	non cut	N/A	N/A	+
#1	-		-	-	-
#3	-	cut	+++	+	+
#4	-		-	N/A	-
#5	-		-	-	-
#6	-	cut	++	+	-
#13	-		-	N/A	-
#14	-		-	-	-
#16	-		-	N/A?	-
#17	-		++	N/A	+
#18	-		-	N/A	-

Table 1). Three positive clones 29, 200, and 362 were selected for blastocyst injection. The genomic DNA from these 3 clones was again confirmed by all of the above methods to be positive prior to blastocyst injection. Clones 200 and 362 had litters that were aborted or cannibalized. Clone 29 generated 6 chimeras with 60 to 90% coat color chimerism. Ten breeding cycles generated no germline transmission.


(2003-2004) Clones 200 and 362 were reinjected, clone 200 generated 5 chimeras with 35 to 60% coat color chimerism, clone 362 generated only one chimera. Six breeding cycles of clone 200 chimeras yielded no germ line transmission. Clone 29 was reinjected, and produced no chimeras.


2) Work performed using targeting construct B.

(2002-2003) The targeting construct was electroporated into ES cells. Positive clones were identified by 5' external probe Southern blots. A PCR strategy to identify 3' integration was also developed. PCR of exon 9 was used to detect the 6xHis-tag, XbaI site, and G525L mutation in the positive clones. Southern blots with an internal probe were also performed to demonstrate only one insertion event in each positive clone. Two positive clones, 55 and 71, were obtained. They were injected into mouse blastocysts and four chimeras, one female from clone 55 and two males and one female from clone 71, were generated. Thus far, germline transmission was not been achieved with any of the chimeras. Therefore, a new set of experiments using a RW4 ES cells and additional refinement of screening procedures were started.

(2003-2004) The mutant G525L ER α targeting construct was electroporated into RW4 ES cells. Clones were initially screened by a Southern blot with a 5' probe external to the targeting construct (Fig 6A). Four positive clones were initially identified. A Southern blot with an internal probe on the 3' end of the targeting construct (Fig 6B), PCR with external 3' sequence primers (Fig 6C), and PCR for identification of the mutant His-tag, added XbaI site (Fig 6D), and G525L mutation (Fig 6E), confirmed only two of these four clones, 42 and 71, had the targeting construct correctly inserted.

Fig. 6





Southern blot and PCR strategies have been developed to genotype the F1 agouti pups (Fig 7).

Future Directions:

- To further confirm the mutant G525L ERα ligand-independent pathways are active in cell culture experiments.
 - The luciferase assay with EGF treatment will be optimized and repeated with the MEK inhibitor U0126 to determine if the effects of EGF on ERE-reporter expression are mediated through MAPK.
- To determine if the nongenomic pathways are still functional with the mutant G525L ERα in cell culture experiments.
 - Ishikawa cells transfected with wt or mutant G525L ERα will be treated with E2 or vehicle for several minutes and ERK1/2 phosphorylation will be analyzed by Western blotting. We anticipate nongenomic signaling pathways will be active in cells expressing mutant G525L ERα.
 - These nongenomic pathways should also not be sensitive to inhibitors of transcription, like α-amanitin and actionmycin D, and translation, like cyclohexamide.
- Clone 42 F1 agouti pups will be genotyped.
 - If germline transmission is successful, heterozygous mice will be bred so homozygous mice can be studied.
 - If germline transmission is not successful, mice will be given genistein or DES to avoid the possible dominant negative effect of the mutant G525L ERα. If this also fails, the His-tag will be removed from the target construct and the electroporation process will be repeated again.

KEY RESEARCH ACCOMPLISHMENTS:

- 1) Ligand binding characterization of the G525L mutant.
- 2) Evaluation of possible dominant negative effects of G525L mutation *in vitro*.
- 3) Preliminary investigation of ligand-independent pathways of G525L ER α .
- 4) Generation of mutant ER chimeras from 2 targeting constructs.

REPORTABLE OUTCOMES:

Abstracts:

- 1) Sugg SL, Li J, Huang JJ, Radek J, Brace J, Swope DL, Korach KS, Greene GL. Design of a transgenic mouse with a regulatable estrogen receptor alpha. Era of Hope Department of Defense Breast Cancer Research Program Meeting, Orlando 2002.
- 2) Sugg SL, Li J, Radek J, Shilyansky J, Greene GL. Differences in Binding Affinity Causes Mutant Estrogen Receptor Alpha Ligand Discrimination. Proc AACR, 2003.

CONCLUSIONS

Over the three years of this award, we have made substantial progress toward creating the transgenic mouse model with a regulatable ER that was proposed for this project. Germline transmission of the G525L mutant ER has been elusive, however. The parent construct had been successfully used in Dr. Korach's laboratory to generate transgenic mice. Two different versions of the construct were able to generate chimeric mice, but no germline transmission has yet occurred despite numerous breeding attempts at two different institutions. Preliminary experiments demonstrate that this is not a result of dominant negative effects of the mutant ER, which could potentially inhibit normal development of the fetal heterozygote mouse. We are continuing to pursue creation of this model, and are awaiting the results of the current round of breeding attempts. Additional experiments have been designed in case of failure, which may be due to the effect of the mutant ER on fetal development, despite the assays showing no dominant negative effect. We are hopeful that the transgenic mice will soon be available. We will then be able to characterize the phenotype, followed by experiments to determine how the timing of ER action affects mammary gland maturation and modulates mammary tumorigenesis and latency in models of genetically and chemically induced mammary cancers. With the widespread clinical use of ER ligands, detailed understanding of ER action is increasingly important. This model will allow us to manipulate ER transcriptional activity *in-vivo* during different developmental stages, and will add significantly to current knowledge on ligand-activated and ligand-independent ER action. Results from our proposal on how the timing of ER activation modulates normal mammary maturation and the development of mammary cancers will likely lead to determining susceptible periods for treatment in the prevention of breast cancer in humans.

REFERENCES

1. Swope DL, Castranio T, Harrell JC, Mishina Y, Korach KS. AF-2 knock-in mutation of estrogen receptor α : cre-loxP excision of a PGK-neo cassette from the 3' UTR. *Genesis*. 2002;32:99-101.
2. Bunting M, Bernstein KE, Greer JM, Capecchi MR, Thomas KR. Targeting genes for self-excision in the germ line. *Genes & Development*. 1999;13:1524-8.

List of personnel receiving pay from the research effort:

- 1) Sonia L Sugg
- 2) Geoffrey Greene
- 3) Jing Li
- 4) Donna McAllister
- 5) Bixia Xiang